Allan Jonathan sold $92K of STOK
Allan Jonathan (GENERAL COUNSEL & CORP SEC) sold 2,861 shares of Stoke Therapeutics, Inc. (STOK) at an average of $32.03 ($32.01–$32.47) across 2 trades on 2026-08-18.
How this was made
The 30-second read
Why it matters
The disclosure updates the record of insider ownership after an open-market sale by the company’s general counsel and corporate secretary role.
Market read
Traders may note insider selling, but the filing lacks any new company catalyst, so it is unlikely to materially reprice the stock by itself.
What to watch
The article provides only sale details, not context such as option exercises, tax planning, or whether other insiders sold/bought around the same time.
Background
The article is a SEC Form 4 insider transaction disclosure for Stoke Therapeutics, Inc.
Ticker impact
Stoke Therapeutics insider Allan Jonathan sold about $91.6K of STOK shares on 2026-08-18 via an open-market sale.
Likely limited near-term impact; any effect is more sentiment/positioning than a new operating catalyst.
The filing is a small, non-10b5-1 sale with no accompanying company news, guidance, or operational update in the text.
Market effects
Minimal, as this is a single-company insider transaction with no sector-wide regulatory or clinical update.
None indicated.
None indicated.
Counterpoint
Insider sales can be planned for liquidity or tax needs; the absence of a 10b5-1 plan does not necessarily imply negative expectations.
Key entities
- issuerStoke Therapeutics, Inc.
Subject of the Form 4 insider sale disclosure (STOK).
- insiderAllan Jonathan
General Counsel and corporate SEC role; sold 2,861 shares on 2026-08-18.
